Skip to main content
Equibles
ETON logo

ETON · Eton Pharmaceuticals, Inc.

Track ETON — free

Use ETON with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ETON

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$58.86 +18.06 (+44.26%) At close · Aug 14
Market Cap
$1.68B
Shares
28.58M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$58.86 Open$54.93 Day$53.01–59.79 52W close$14.35–58.86 Avg vol 30d575K Short int1.3M · 4.6% float · 2.1d Short vol40% Last earningsAug 13, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 13

Up next

Next earnings call
Nov 12, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +135%
      above
      Price vs 50-day avg +52%
      above
      RSI (14) 76
      overbought
      MACD trend Positive
      52-week position 100%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +39%
      trailing
      6-month return +222%
      trailing
      YTD return +248%
      this year
      Relative strength +208%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $39 › 200d $25 — 50d above 200d
      Institutional flow Accumulating
      +40% holders QoQ · +54 funds added
      Insider flow Distributing
      Net -$14.5M over 90 days · 100% sells
      Short interest Rising
      4.59% of float · ▲ +7.1% MoM · 2.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      162 holders — near 3-yr high, broad support
      Squeeze score 88
      high risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +105%
      Y/Y
      Gross margin 53%
      contracting
      Free cash flow $10.2M
      Balance sheet $4.6M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 70%
      annualized · 1-yr
      Max drawdown −36%
      past year
      ATR 6.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the Earnings Call filed Aug 13, 2026
      full year 2026
      Full year revenue Initiated at least $145M
      prior FY $79.95M midpoint +81.4% Y/Y
      Full year adjusted EBITDA margin Non-GAAP Initiated at least 35%
      full year
      Full-year adjusted gross margin Non-GAAP at least 70%
      Full year R&D spending $10M – $14M
      Prior guidance period ended · from the 8-K filed Nov 6, 2025
      Adjusted gross margin · fourth quarter 70%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 2 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +135% Bullish
      Price vs 50-day avg
      +52% Bullish
      RSI (14)
      76 Bearish
      MACD trend
      Positive Bullish
      52-week position
      100% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $39 › 200d $25 — 50d above 200d
      Institutional flow Accumulating
      +40% holders QoQ · +54 funds added
      Insider flow Distributing
      Net -$14.5M over 90 days · 100% sells
      Short interest Rising
      4.59% of float · ▲ +7.1% MoM · 2.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      162 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $14 Now $59 · 100% Range high $59
      vs 200-day avg +135% vs 50-day avg +52%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted EBITDA margin non-GAAP 43% Q2 2026 —
      active patients on GALZIN 300 Q4 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      ETON
      Eton Pharmaceuticals, Inc.
      this stock
      		$1.68B +248.1% +104.9% — 4.6%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      		 $64.91B — — — 0.0%
      TAK
      Takeda Pharmaceutical Co Ltd
      		 $56.30B +13.1% — — 0.1%
      GALDY
      Galderma Group AG/ADR
      		 $49.49B +2.4% — — 0.0%
      TEVA
      Teva Pharmaceutical Industries Ltd
      		 $42.85B +17.8% +4.3% 60.3 2.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      162
      % held
      69.8%
      Net QoQ
      +1.9M sh
      Top holder
      Opaleye Management Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      99
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      1.3M
      Days to cover
      2.1d
      Change
      +87.1K sh
      View
      Short Volume
      Short vol %
      40%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      51
      Value
      $1.9K
      As of
      Jul 14, 2026
      View
      Off-Exchange
      Off-exchange %
      44.5%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$14.5M
      Buyers / Sellers
      0 / 4
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $80.0M
      Net income (FY)
      $-4.6M
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 13, 2026
      This year
      20
      View
      Proposed Sales
      Value
      $9.0M
      Shares
      251.8K
      Filed
      Jun 26, 2026
      View
      Exempt Offerings
      Offering
      $7.5M
      Filed
      Apr 8, 2020
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      ETON +32.0% +39.1% +222.0% +26.8% +248.1%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +31.6% +34.6% +208.2% +22.9% +234.2%
      Key facts CIK 1710340 CUSIP 29772L108 13F (30d) 156 filings 154 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)